OTCMSRNMF
Market cap42mUSD
, Last price
USD
Name
Sirnaomics Ltd
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
397k
-43.69%
Net income
-79m
L-10.88%
CFO
-70m
L-20.76%
Profile
Sirnaomics Ltd., an RNA therapeutics biopharmaceutical company, focuses on the discovery and development of product candidates for indications with medical needs in the United Sates and the People's Republic of China. Its lead product candidates include STP705 for the treatment cutaneous squamous cell carcinoma in situ; basal cell carcinoma; cholangiocarcinoma, hepatocellular carcinoma, liver metastases, etc.; keloid scarless healing, hypertrophic scarring, and fat sculpting. The company's lead product candidates also comprise STP707 to treat cholangiocarcinoma, hepatocellular carcinoma, liver metastases, etc.; metastatic cutaneous squamous cell carcinoma; non-small cell lung cancer; liver fibrosis; and lung fibrosis. It also develops STP355 for the treatment of pan cancer; STP369 to treat head and neck/bladder cancer; STP779 for the treatment of liver/lung/pancreatic cancer; STP902 to treat breast cancer; STP702 for the treatment of influenza; STP908 to treat COVID-19; RIM730 COVID-19 vaccine; STP909 for the treatment of HPV/cervical cancer; and STP122G for thrombotic disorders. In addition, the company is developing STP125G to treat hypertriglyceridemia; STP144G for the treatment of complement-mediated diseases; STP133G for cardiometabolic; and STP155G for the treatment hepatitis B virus. Sirnaomics Ltd. was founded in 2007 and is headquartered in Gaithersburg, Maryland.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | 397 -43.69% | 705 892.96% | |||
Cost of revenue | 77,543 | 93,624 | |||
Unusual Expense (Income) | |||||
NOPBT | (77,146) | (92,919) | |||
NOPBT Margin | |||||
Operating Taxes | (9,079) | ||||
Tax Rate | |||||
NOPAT | (77,146) | (83,840) | |||
Net income | (78,691) -10.88% | (88,299) -58.56% | |||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | (5,432) | 72 | |||
BB yield | 0.20% | 0.00% | |||
| Debt | |||||
Debt current | 1,179 | 1,751 | |||
Long-term debt | 16,511 | 19,761 | |||
Deferred revenue | |||||
Other long-term liabilities | 30,651 | 29,139 | |||
Net debt | (26,237) | (98,721) | |||
| Cash flow | |||||
Cash from operating activities | (70,292) | (88,708) | |||
CAPEX | (1,742) | (18,830) | |||
Cash from investing activities | (5,350) | (32,611) | |||
Cash from financing activities | (5,606) | 15,888 | |||
FCF | (66,065) | (98,645) | |||
| Balance | |||||
Cash | 43,927 | 105,229 | |||
Long term investments | 15,004 | ||||
Excess cash | 43,907 | 120,198 | |||
Stockholders' equity | (489,505) | (404,683) | |||
Invested Capital | 553,458 | 556,138 | |||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 76,056 | 76,008 | |||
Price | 35.80 -38.06% | 57.80 -25.80% | |||
Market cap | 2,722,796 -38.02% | 4,393,280 278.57% | |||
EV | 2,680,820 | 4,285,473 | |||
EBITDA | (70,987) | (88,986) | |||
EV/EBITDA | |||||
Interest | 798 | ||||
Interest/NOPBT | |||||